SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
F. Wang(Sun Yat-sen University), Renjie Xu(Sun Yat-sen University), Fuxiang Zhou(Wuhan University), Zhigang Ma(Gansu Provincial Hospital), Yanglong Guo(Sun Yat-sen University), X. Hu(Guangxi Medical University), Junlan Xiao(Sun Yat-sen University), Zhi‐Ying Mai(Sun Yat-sen University), Zengqing Guo(Fujian Provincial Cancer Hospital), Wen‐Feng Fang(Sun Yat-sen University), Zhixiang Zhuang(Soochow University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiumei Wu(Sun Yat-sen University), W. Wang(First People's Hospital of Foshan), Qing-Feng Zou(Guangzhou Medical University Cancer Hospital), Y. Zhang(Harbin Medical University), Ming-Ming He(Sun Yat-sen University), Xianglin Yuan(Tongji Hospital), Yu Yao(Sun Yat-sen University), Yexian Yuan(Second Affiliated Hospital of Zhejiang University), Ying Jin(Sun Yat-sen University), Y. Zhang(Harbin Medical University)
Cited by 5
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417